Dava Pharmaceuticals, Inc. Products: Prescription Medications Section

Bicalutamide

Bicalutamide Tablets. USP 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. Bicalutamide Tablets. USP 150 mg daily…

Dava Pharmaceuticals, Inc.17 July 2009

DrugInserts.com

Information Sections

RSS Feeds

About

As the leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. Our material is not intended as a substitute for direct consultation with a qualified health professional.